你好！欢迎访问登录|立即注册

中文|

0576-88813233

|

关于885566威尼斯

885566威尼斯产品

关于885566威尼斯

885566威尼斯产品

- 客户定制产品 - 前列腺素系列 - PI3K Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - mTOR Inhibitors - c-Met Inhibitors - DNA/RNA Inhibitors - HER2 Inhibitors - Raf Inhibitors - JAK Inhibitors - Others - SRC Inhibitors - AKT Inhibitors - CDK Inhibitors

浙江省台州市椒江开发大道东段288号万达广场2号楼

0576-88813233

0576-88670057

sales@dxymsy.com

合作客户/Partner

当前位置：885566威尼斯产品

帕布昔利布Palbociclib

帕布昔利布Palbociclib 571190-30-2

规格	价格	库存	数量
大包装询价加入购物车

如您需要更多数量的报价，请点击立即获取报价或者通过电子邮件sales@dxymsy.com把您需要的数量信息提交给我们我们会在第一时间回复您，谢谢！

产品信息

产品名称：帕布昔利布Palbociclib	纯度：99%min
CAS NO：571190-30-2	溶解度：Soluble in DMSO
分子式：C₂₄H₂₉N₇O₂	包装：可按客户要求包装。
分子量：447.53	贮存：Store at -20℃ 3 years

质量控制

备注说明

帕布昔利布Palbociclib是一种高特异性的 Cdk4 和 Cdk6 抑制剂，IC₅₀ 分别为 11 nM 和 16 nM.The IC₅₀ of Palbociclib (PD 0332991) for reduction of retinoblastoma (Rb) phosphorylation at Ser⁷⁸⁰ in MDA-MB-435 breast carcinoma cells is 66 nM. Palbociclib is equally effective at reducing Rb phosphorylation at Ser⁷⁹⁵ in this tumor with an IC₅₀ of 63 nM, and similar effects on both Ser⁷⁸⁰ and Ser⁷⁹⁵ phosphorylation are obtained in the Colo-205 colon carcinoma^[1]. The MP-MRT-AN (AN), KP-MRT-RY (RY), G401, and KP-MRT-NS (NS) cell lines are effectively inhibited by Palbociclib (PD) in a concentration-dependent manner in a WST-8 assay. The IC₅₀s are 0.01 µM, 0.01 µM, 0.06 µM, and 0.6 µM, respectively. In contrast, the KP-MRT-YM (YM) cell line is resistant to Palbociclib (IC₅₀>10 µM). The flow cytometry results show that Palbociclib at concentrations between 0 to 1.0 µM induces G1 arrest in the AN, RY, G401 and NS cell lines in a concentration-dependent manner, but has no effect on YM cells. The BrdU incorporation results are consistent with the WST-8 and flow cytometry results: PD reduces BrdU incorporation (indicating G1 arrest) in the AN, RY, G401 and NS cell lines, but not in the YM cell line. Palbociclib, even at a concentration of 0.05 µM, significantly reduces BrdU incorporation in the AN, RY, and G401 cell lines (p<0.05)^[2].Palbociclib (PD 0332991) exhibits significant antitumor efficacy against multiple human tumor xenograft models. In mice bearing Colo-205 colon carcinoma xenografts (p16 deleted), daily p.o. dosing for 14 days with Palbociclib (150 or 75 mg/kg) produces rapid tumor regressions and a corresponding tumor growth delay of ~50 days with >1 log of tumor cell kill at the highest dose tested. At 37.5 mg/kg, the tumor slowly regressed during treatment. Even at doses as low as 12.5 mg/kg, a 13-day growth delay is obtained indicating a 90% inhibition of tumor growth rate. Likewise, robust antitumor activity is seen in the MDA-MB-435 breast carcinoma (p16 deleted) where complete tumor stasis is apparent at 150 mg/kg and some cell kill is evident at the highest dose^[1].

参考文献

[1].

[2].

[3].

首页| 关于885566威尼斯| 885566威尼斯产品| 定制中心| 客户服务| 如何订购| 新闻中心| 积分换礼| 联系我们

版权所有 Copyright(C) 2018-2024 台州市885566威尼斯生物技术有限公司

技术支持：kerui 浙ICP备09021343号-1

公司所列产品中涉及到专利，只供研发使用，不做销售；管制产品将严格遵守中国法律和购买客户国法律的规定销售，所有产品都不适用于人用如被销售到构成专利侵权的国家，则相应的一切风险将由买方承担。